NRIXNurix Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 23). Price is +16% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NRIX is trading
Nurix Therapeutics, Inc. is +165% over the past year while the S&P 500 is +18%: 147 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +16%
vs 200-day average · a clear uptrend
- RSI (14)
- 23
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 20%
Below its 52-week high
Details›
- Last close2026-10-09
- $22.36
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +165%
- 5 yearsS&P 500 +88%
- −37%
- vs 50-day average$25.13
- −11%
- 52-week high
- $27.79
- 52-week low
- $8.24
- Annualised volatility
- 61%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$393K
| Year | Return |
|---|---|
| 2026 (year to date) | +18% |
| 2025 | +0.69% |
| 2024 | +83% |
| 2023 | −6.0% |
| 2022 | −62% |
| 2021 | −12% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | −7.5% |
| Feb | 6 | 1 of 6 | −1.2% |
| Mar | 6 | 1 of 6 | −6.5% |
| Apr | 6 | 3 of 6 | −2.3% |
| May | 6 | 3 of 6 | +0.99% |
| Jun | 6 | 4 of 6 | +14% |
| Jul | 6 | 4 of 6 | +8.4% |
| Aug | 7 | 4 of 7 | +2.3% |
| Sep | 7 | 1 of 7 | −0.36% |
| Oct | 7 | 3 of 7 | −0.46% |
| Nov | 6 | 3 of 6 | +15% |
| Dec | 6 | 3 of 6 | +4.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.